Systemic Lupus Erythematosus: From Genes to Organ Damage (original) (raw)

References

1. Krishnan S, Chowdhury B, Juang Y-T, Tsokos GC (2007) Overview of the pathogenesis of systemic lupus erythematosus. In: Tsokos GC, Gordon C, Smolen JS (eds) Systemic lupus erythematosus: a companion to Rheumatology, 1st edn. Mosby Inc, Philadelphia, pp 55–63
   Chapter Google Scholar
2. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778–799
   Article CAS PubMed Google Scholar
3. McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK (1995) Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 38:1260–1270
   Article CAS PubMed Google Scholar
4. Siegel M, Lee SL (1973) The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum 3:1–54
   Article CAS PubMed Google Scholar
5. Nossent JC (1992) Systemic lupus erythematosus on the Caribbean island of Curacao: an epidemiological investigation. Ann Rheum Dis 51:1197–1201
   Article CAS PubMed PubMed Central Google Scholar
6. Vilar MJ, Sato EI (2002) Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil). Lupus 11:528–532
   Article PubMed Google Scholar
7. McCarty DJ, Manzi S, Medsger TA Jr et al (1995) Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 38:1260–1270
   Article CAS PubMed Google Scholar
8. Lahita RG (1999) The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 11:352–356
   Article CAS PubMed Google Scholar
9. Voulgari PV, Katsimbri P, Alamanos Y, Drosos AA (2002) Gender and age differences in systemic lupus erythematosus. A study of 489 Greek patients with a review of the literature. Lupus 11:722–729
   Article CAS PubMed Google Scholar
10. Soto ME, Vallejo M, Guillen F, Simon JA, Arena E, Reyes PA (2004) Gender impact in systemic lupus erythematosus. Clin Exp Rheumatol 22:713–721
    CAS PubMed Google Scholar
11. Tucker LB, Menon S, Isenberg DA (1995) Systemic lupus in children: daughter of the Hydra? Lupus 4:83–85
    Article CAS PubMed Google Scholar
12. Mak SK, Lam EK, Wong AK (1998) Clinical profile of patients with late-onset SLE: not a benign subgroup. Lupus 7:23–28
    Article CAS PubMed Google Scholar
13. Baker SB, Rovira JR, Campion EW, Mills JA (1979) Late onset systemic lupus erythematosus. Am J Med 66:727–732
    Article CAS PubMed Google Scholar
14. Hochberg MC (1985) The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970–1977. Arthritis Rheum 28:80–86
    Article CAS PubMed Google Scholar
15. Ward MM, Studenski S (1990) Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences. Arch Intern Med 150:849–853
    Article CAS PubMed Google Scholar
16. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, Walker A, Mack TM (1992) A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35:311–318
    Article CAS PubMed Google Scholar
17. Werth VP (2005) Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev 4:296–302
    Article PubMed Google Scholar
18. James JA, Neas BR, Moser KL, Hall T, Bruner GR, Sestak AL, Harley JB (2001) Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 44:1122–1126
    Article CAS PubMed Google Scholar
19. Hochberg M (1997) Updating the American College of Rheumatology Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
    Article CAS PubMed Google Scholar
20. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Domenech I, Aydintug AO, Jedryka-Goral A, de Ramon E et al (1993) Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1, 000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 72:113–124
    Article CAS Google Scholar
21. Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, Abadi I, Caeiro F, Alvarellos A, Alarcon-Segovia D (2004) The GLADEL multinational Latin American prospective inception cohort of 1, 214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine (Baltimore) 83:1–17
    Article Google Scholar
22. Boumpas DT, Fessler BJ, Austin HA III, Balow JE, Klippel JH, Lockshin MD (1995) Systemic lupus erythematosus: emerging concepts. Part 2: dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 123:42–53
    Article CAS PubMed Google Scholar
23. Boumpas DT, Austin HA III, Fessler BJ, Balow JE, Klippel JH, Lockshin MD (1995) Systemic lupus erythematosus: emerging concepts. Part 1: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 122:940–950
    Article CAS PubMed Google Scholar
24. Al-Maini M, Urowitz M (2007) Systemic steroids. In: Tsokos GC, Gordon C, Smolen JS (eds) Systemic lupus erythematosus: a companion to Rheumatology, 1st edn. Mosby Inc, Philadelphia, pp 487–498
    Chapter Google Scholar
25. Papadimitraki E, Boumpas DD (2007) Cytotoxic drug treatment. In: Tsokos GC, Gordon C, Smolen JS (eds) Systemic lupus erythematosus: a companion to Rheumatology, 1st edn. Mosby Inc, Philadelphia, pp 498–510
    Google Scholar
26. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228
    Article CAS PubMed Google Scholar
27. Houssiau FA, Ginzler EM (2008) Current treatment of lupus nephritis. Lupus 17:426–430
    Article CAS PubMed Google Scholar
28. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y (2004) Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34:501–537
    Article CAS PubMed Google Scholar
29. Rahman A, Hiepe F (2002) Anti-DNA antibodies – overview of assays and clinical correlations. Lupus 11:770–773
    Article CAS PubMed Google Scholar
30. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533
    Article CAS PubMed Google Scholar
31. Illei GG, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus. Curr Rheumatol Rep 6:382–390
    Article PubMed Google Scholar
32. Jerdan MS, Hood AF, Moore GW, Callen JP (1990) Histopathologic comparison of the subsets of lupus erythematosus. Arch Dermatol 126:52–55
    Article CAS PubMed Google Scholar
33. Tsao BP (2004) Update on human systemic lupus erythematosus genetics. Curr Opin Rheumatol 16:513–521
    Article CAS PubMed Google Scholar
34. Graham RR, Ortmann WA, Langefeld CD, Jawaheer D, Selby SA, Rodine PR, Baechler EC, Rohlf KE, Shark KB, Espe KJ, Green LE, Nair RP, Stuart PE, Elder JT, King RA, Moser KL, Gaffney PM, Bugawan TL, Erlich HA, Rich SS, Gregersen PK, Behrens TW (2002) Visualizing human leukocyte antigen class II risk haplotypes in human systemic lupus erythematosus. Am J Hum Genet 71:543–553
    Article CAS PubMed PubMed Central Google Scholar
35. Galeazzi M, Sebastiani GD, Morozzi G, Carcassi C, Ferrara GB, Scorza R, Cervera R, de Ramon Garrido E, Fernandez-Nebro A, Houssiau F, Jedryka-Goral A, Passiu G, Papasteriades C, Piette JC, Smolen J, Porciello G, Marcolongo R (2002) HLA class II DNA typing in a large series of European patients with systemic lupus erythematosus: correlations with clinical and autoantibody subsets. Medicine (Baltimore) 81:169–178
    Article CAS Google Scholar
36. Rajagopalan S, Zordan T, Tsokos GC, Datta SK (1990) Pathogenic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: isolation of CD4-8- T helper cell lines that express the gamma delta T-cell antigen receptor. Proc Natl Acad Sci USA 87:7020–7024
    Article CAS PubMed PubMed Central Google Scholar
37. Shivakumar S, Tsokos GC, Datta SK (1989) T cell receptor alpha/beta expressing double-negative (CD4−/CD8−) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 143:103–112
    CAS PubMed Google Scholar
38. Liossis SN, Ding XZ, Dennis GJ, Tsokos GC (1998) Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest 101:1448–1457
    Article CAS PubMed PubMed Central Google Scholar
39. Krishnan S, Nambiar MP, Warke VG, Fisher CU, Mitchell J, Delaney N, Tsokos GC (2004) Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol 172:7821–7831
    Article CAS PubMed Google Scholar
40. Enyedy EJ, Nambiar MP, Liossis SN, Dennis G, Kammer GM, Tsokos GC (2001) Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum 44:1114–1121
    Article CAS PubMed Google Scholar
41. Tsokos GC, Nambiar MP, Tenbrock K, Juang YT (2003) Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol 24:259–263
    Article CAS PubMed Google Scholar
42. Krishnan S, Warke VG, Nambiar MP, Tsokos GC, Farber DL (2003) The FcR gamma subunit and Syk kinase replace the CD3 zeta-chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells. J Immunol 170:4189–4195
    Article CAS PubMed Google Scholar
43. Juang YT, Tenbrock K, Nambiar MP, Gourley MF, Tsokos GC (2002) Defective production of functional 98-kDa form of Elf-1 is responsible for the decreased expression of TCR zeta-chain in patients with systemic lupus erythematosus. J Immunol 169:6048–6055
    Article CAS PubMed Google Scholar
44. Chowdhury B, Tsokos CG, Krishnan S, Robertson J, Fisher CU, Warke RG, Warke VG, Nambiar MP, Tsokos GC (2005) Decreased stability and translation of T cell receptor zeta mRNA with an alternatively spliced 3′-untranslated region contribute to zeta chain down-regulation in patients with systemic lupus erythematosus. J Biol Chem 280:18959–18966
    Article CAS PubMed Google Scholar
45. Tsuzaka K, Setoyama Y, Yoshimoto K, Shiraishi K, Suzuki K, Abe T, Takeuchi T (2005) A splice variant of the TCR zeta mRNA lacking exon 7 leads to the down-regulation of TCR zeta, the TCR/CD3 complex, and IL-2 production in systemic lupus erythematosus T cells. J Immunol 174:3518–3525
    Article CAS PubMed Google Scholar
46. Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA (1983) Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 130:2651–2655
    CAS PubMed Google Scholar
47. Valencia X, Yarboro C, Illei G, Lipsky PE (2007) Deficient CD4 + CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 178:2579–2588
    Article CAS PubMed Google Scholar
48. Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, Nochy D, Debre P, Piette JC, Gorochov G (2005) Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 175:8392–8400
    Article CAS PubMed Google Scholar
49. Herndon TM, Juang YT, Solomou EE, Rothwell SW, Gourley MF, Tsokos GC (2002) Direct transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin-2 promoter activity. Clin Immunol 103:145–153
    Article CAS PubMed Google Scholar
50. Kyttaris VC, Juang YT, Tenbrock K, Weinstein A, Tsokos GC (2004) Cyclic adenosine 5′-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J Immunol 173:3557–3563
    Article CAS PubMed Google Scholar
51. Katsiari CG, Kyttaris VC, Juang YT, Tsokos GC (2005) Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J Clin Invest 115:3193–3204
    Article CAS PubMed PubMed Central Google Scholar
52. Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC (2001) Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol 166:4216–4222
    Article CAS PubMed Google Scholar
53. Tenbrock K, Juang YT, Gourley MF, Nambiar MP, Tsokos GC (2002) Antisense cyclic adenosine 5′-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus. J Immunol 169:4147–4152
    Article CAS PubMed Google Scholar
54. Kyttaris VC, Wang Y, Juang YT, Weinstein A, Tsokos GC (2007) Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in t cells from patients with systemic lupus erythematosus. J Immunol 178:1960–1966
    Article CAS PubMed Google Scholar
55. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK (1996) Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97:2063–2073
    Article CAS PubMed PubMed Central Google Scholar
56. Xu L, Zhang L, Yi Y, Kang HK, Datta SK (2004) Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 10:411–415
    Article CAS PubMed Google Scholar
57. Li Y, Harada T, Juang YT, Kyttaris VC, Wang Y, Zidanic M, Tung K, Tsokos GC (2007) Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J Immunol 178:1938–1947
    Article CAS PubMed Google Scholar
58. Crispin JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, Kyttaris VC, Juang YT, Tsokos GC (2008) Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 181:8761–8766
    Article CAS PubMed PubMed Central Google Scholar
59. Baroja ML, Vijayakrishnan L, Bettelli E, Darlington PJ, Chau TA, Ling V, Collins M, Carreno BM, Madrenas J, Kuchroo VK (2002) Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A. J Immunol 168:5070–5078
    Article CAS PubMed Google Scholar
60. Salomon B, Bluestone JA (2001) Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19:225–252
    Article CAS PubMed Google Scholar
61. Hudson LL, Rocca K, Song YW, Pandey JP (2002) CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet 111:452–455
    Article CAS PubMed Google Scholar
62. Wong CK, Lit LCW, Tam LS, Li EK, Lam CWK (2005) Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 44:989–994
    Article CAS Google Scholar
63. Cloutier JF, Veillette A (1996) Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells. EMBO J 15:4909–4918
    CAS PubMed PubMed Central Google Scholar
64. Cloutier JF, Veillette A (1999) Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 189:111–121
    Article CAS PubMed PubMed Central Google Scholar
65. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, Chang M, Ramos P, Baechler EC, Batliwalla FM, Novitzke J, Williams AH, Gillett C, Rodine P, Graham RR, Ardlie KG, Gaffney PM, Moser KL, Petri M, Begovich AB, Gregersen PK, Behrens TW (2004) Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 75:504–507
    Article CAS PubMed PubMed Central Google Scholar
66. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE (2005) Identification and characterization of circulating human transitional B cells. Blood 105:4390–4398
    Article CAS PubMed PubMed Central Google Scholar
67. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC (2005) Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 201:703–711
    Article CAS PubMed PubMed Central Google Scholar
68. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira RC, Pant PV, Ballinger DG, Kosoy R, Demirci FY, Kamboh MI, Kao AH, Tian C, Gunnarsson I, Bengtsson AA, Rantapaa-Dahlqvist S, Petri M, Manzi S, Seldin MF, Ronnblom L, Syvanen AC, Criswell LA, Gregersen PK, Behrens TW (2008) Association of Systemic Lupus Erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 358:900–909
    Article CAS PubMed Google Scholar
69. Tretter T, Ross AE, Dordai DI, Desiderio S (2003) Mimicry of pre-B cell receptor signaling by activation of the tyrosine kinase Blk. J Exp Med 198:1863–1873
    Article CAS PubMed PubMed Central Google Scholar
70. Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC (1996) B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 98:2549–2557
    Article CAS PubMed PubMed Central Google Scholar
71. Enyedy EJ, Mitchell JP, Nambiar MP, Tsokos GC (2001) Defective FcgammaRIIb1 signaling contributes to enhanced calcium response in B cells from patients with systemic lupus erythematosus. Clin Immunol 101:130–135
    Article CAS PubMed Google Scholar
72. Mackay M, Stanevsky A, Wang T, Aranow C, Li M, Koenig S, Ravetch JV, Diamond B (2006) Selective dysregulation of the Fc{gamma}IIB receptor on memory B cells in SLE. J Exp Med 203:2157–2164
    Article CAS PubMed PubMed Central Google Scholar
73. Juang YT, Wang Y, Solomou EE, Li Y, Mawrin C, Tenbrock K, Kyttaris VC, Tsokos GC (2005) Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 115:996–1005
    Article CAS PubMed PubMed Central Google Scholar
74. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB (1998) Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 188:2313–2320
    Article CAS PubMed PubMed Central Google Scholar
75. Manderson AP, Botto M, Walport MJ (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22:431–456
    Article CAS PubMed Google Scholar
76. Ghebrehiwet B, Peerschke EI (2004) Role of C1q and C1q receptors in the pathogenesis of systemic lupus erythematosus. Curr Dir Autoimmun 7:87–97
    Article CAS PubMed Google Scholar
77. Slingsby JH, Norsworthy P, Pearce G, Vaishnaw AK, Issler H, Morley BJ, Walport MJ (1996) Homozygous hereditary C1q deficiency and systemic lupus erythematosus. A new family and the molecular basis of C1q deficiency in three families. Arthritis Rheum 39:663–670
    Article CAS PubMed Google Scholar
78. Senaldi G, Davies ET, Peakman M, Vergani D, Lu J, Reid KB (1995) Frequency of mannose-binding protein deficiency in patients with systemic lupus erythematosus. Arthritis Rheum 38:1713–1714
    Article CAS PubMed Google Scholar
79. Sullivan KE, Wooten C, Goldman D, Petri M (1996) Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. Arthritis Rheum 39:2046–2051
    Article CAS PubMed Google Scholar
80. Iliopoulos AG, Tsokos GC (1996) Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 25:318–336
    Article CAS PubMed Google Scholar
81. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW (1999) The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med 190:585–590
    Article CAS PubMed PubMed Central Google Scholar
82. Salmon JE, Pricop L (2001) Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease. Arthritis Rheum 44:739–750
    Article CAS PubMed Google Scholar
83. Karassa FB, Trikalinos TA, Ioannidis JP (2002) Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum 46:1563–1571
    Article CAS PubMed Google Scholar
84. Karassa FB, Trikalinos TA, Ioannidis JP (2003) The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. Kidney Int 63:1475–1482
    Article CAS PubMed Google Scholar
85. Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J, Powell RJ, Isenberg DA, Walport MJ, Vyse TJ (2004) Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 13:137–147
    Article CAS PubMed PubMed Central Google Scholar
86. Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, Kuroda Y (2001) Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 28:313–314
    Article CAS PubMed Google Scholar
87. Kyttaris VC, Juang YT, Tsokos GC (2005) Immune cells and cytokines in systemic lupus erythematosus: an update. Curr Opin Rheumatol 17:518–522
    Article CAS PubMed Google Scholar
88. Wilson AG, Gordon C, di Giovine FS, de Vries N, van de Putte LB, Emery P, Duff GW (1994) A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol 24:191–195
    Article CAS PubMed Google Scholar
89. D’Alfonso S, Rampi M, Bocchio D, Colombo G, Scorza-Smeraldi R, Momigliano-Richardi P (2000) Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum 43:120–128
    Article PubMed Google Scholar
90. Morita C, Horiuchi T, Tsukamoto H, Hatta N, Kikuchi Y, Arinobu Y, Otsuka T, Sawabe T, Harashima S, Nagasawa K, Niho Y (2001) Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 44:2819–2827
    Article CAS PubMed Google Scholar
91. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK (2005) Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52:1491–1503
    Article CAS PubMed Google Scholar
92. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PIW, Le JM, Lee H-S, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gregersen PK (2007) STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357:977–986
    Article CAS PubMed PubMed Central Google Scholar
93. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, Gonzalez Escribano MF, Pons-Estel B, Petri M, Daly M, Gregersen PK, Martin J, Altshuler D, Behrens TW, Alarcon-Riquelme ME (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38:550–555
    Article CAS PubMed Google Scholar
94. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, Kano S, Honda K, Ohba Y, Mak TW, Taniguchi T (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434:243–249
    Article CAS PubMed Google Scholar

Download references